Does Screening Save Lives?
Data from a large-scale trial suggest that screening cuts ovarian cancer mortality rates by 25 percent – but some remain skeptical
The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is one of the largest clinical trials ever conducted worldwide – 202,000 women in 13 regions across the UK are involved. The study estimates a 15–28 percent reduction in mortality attributable to ovarian cancer screening via annual blood tests for CA125 (1), but many have reacted with caution at this stage. We spoke with lead author Ian Jacobs, professor at University College London’s Department of Women's Cancer, to find out more.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!